Performance Period: 10/1/2020 to 1/31/2022
This proposal aims to use a generic, label-free approach to assay cultured cells in-process during viral vaccine production for extent of infection based on laser-force cytology (LFC). LFC has no requirement for the use of specific probes, giving a general test of viral infectivity, and has been applied to viral infectivity and in-process measurements in vaccine production. This particular application presents challenges; one is that the cells need to be isolated from microcarriers for LFC analysis and another is that any infection by adventitious agent (AA) needs to be discriminated from infection by the production viral carrier (VC).
We will address these by implementing a microfluidic device to isolate cells from microcarriers and by quantifying levels of AA and VC in spiked bioprocesses using high-affinity nucleic acid probes in a rapid, high-sensitivity form of electrophoresis (micelle-tagging electrophoresis, MTE). This information will be fed into a mathematical model of infection progress to better predict the concentration of infected and non-infected cells at time points and maximize the sensitivity of LFC. We will also demonstrate the effectiveness of LFC for non-viral biomanufacturing processes, and to establish MTE as a rapid and quantitative means to assay viral capsids in bioprocesses.
General test for viral infectivity in cultured cells without requiring the use of specific probes
Reduce the amount of time required by an assay to detect virus in cultured cells thus lowering the cost of a contamination event and resulting in less drug supply lost
Cultured cells analyzed for infectivity in real time (hundreds of cells analyzed in less than 5 minutes)
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
Carnegie Mellon University